Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Complete Title: A phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated breast cancer
Trial Phase: II
Investigator: Jennifer Specht
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: Niraparib (Zejula) Dostarlimab
Keywords:
- Breast Cancer
- Triple Negative Breast Neoplasms
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Jennifer Specht
RG1122984
NCT04584255
A phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated breast cancer
Breast Cancer
Triple Negative Breast Neoplasms